Cargando…

Advances in limb salvage treatment of osteosarcoma

Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yichun, Han, Lei, He, Zewei, Li, Xiaojuan, Yang, Suping, Yang, Jifei, Zhang, Ya, Li, Dongqi, Yang, Yihao, Yang, Zuozhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739147/
https://www.ncbi.nlm.nih.gov/pubmed/29296558
http://dx.doi.org/10.1016/j.jbo.2017.11.005
_version_ 1783287814816792576
author Yang, Yichun
Han, Lei
He, Zewei
Li, Xiaojuan
Yang, Suping
Yang, Jifei
Zhang, Ya
Li, Dongqi
Yang, Yihao
Yang, Zuozhang
author_facet Yang, Yichun
Han, Lei
He, Zewei
Li, Xiaojuan
Yang, Suping
Yang, Jifei
Zhang, Ya
Li, Dongqi
Yang, Yihao
Yang, Zuozhang
author_sort Yang, Yichun
collection PubMed
description Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients with limb salvage was not inferior to that of amputees, and therefore, limb salvage has become the main surgical option for patients with osteosarcoma. The 5-year survival rate for osteosarcoma has plateaued. However, new advances in limb salvage therapy in osteosarcoma, including adjuvant chemotherapy, ablation techniques, bone transport techniques, and computer navigation techniques, are now available. This report summarizes the recent advances in limb salvage therapy for osteosarcoma over the past decade.
format Online
Article
Text
id pubmed-5739147
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-57391472018-01-02 Advances in limb salvage treatment of osteosarcoma Yang, Yichun Han, Lei He, Zewei Li, Xiaojuan Yang, Suping Yang, Jifei Zhang, Ya Li, Dongqi Yang, Yihao Yang, Zuozhang J Bone Oncol Review Article Osteosarcoma is the most common primary malignant bone tumor; its standard treatment includes neoadjuvant chemotherapy combined with surgery. Neoadjuvant chemotherapy has significantly improved the 5-year survival and limb salvage rates in osteosarcoma since the 1870s. The survival rate of patients with limb salvage was not inferior to that of amputees, and therefore, limb salvage has become the main surgical option for patients with osteosarcoma. The 5-year survival rate for osteosarcoma has plateaued. However, new advances in limb salvage therapy in osteosarcoma, including adjuvant chemotherapy, ablation techniques, bone transport techniques, and computer navigation techniques, are now available. This report summarizes the recent advances in limb salvage therapy for osteosarcoma over the past decade. Elsevier 2017-11-26 /pmc/articles/PMC5739147/ /pubmed/29296558 http://dx.doi.org/10.1016/j.jbo.2017.11.005 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Yang, Yichun
Han, Lei
He, Zewei
Li, Xiaojuan
Yang, Suping
Yang, Jifei
Zhang, Ya
Li, Dongqi
Yang, Yihao
Yang, Zuozhang
Advances in limb salvage treatment of osteosarcoma
title Advances in limb salvage treatment of osteosarcoma
title_full Advances in limb salvage treatment of osteosarcoma
title_fullStr Advances in limb salvage treatment of osteosarcoma
title_full_unstemmed Advances in limb salvage treatment of osteosarcoma
title_short Advances in limb salvage treatment of osteosarcoma
title_sort advances in limb salvage treatment of osteosarcoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739147/
https://www.ncbi.nlm.nih.gov/pubmed/29296558
http://dx.doi.org/10.1016/j.jbo.2017.11.005
work_keys_str_mv AT yangyichun advancesinlimbsalvagetreatmentofosteosarcoma
AT hanlei advancesinlimbsalvagetreatmentofosteosarcoma
AT hezewei advancesinlimbsalvagetreatmentofosteosarcoma
AT lixiaojuan advancesinlimbsalvagetreatmentofosteosarcoma
AT yangsuping advancesinlimbsalvagetreatmentofosteosarcoma
AT yangjifei advancesinlimbsalvagetreatmentofosteosarcoma
AT zhangya advancesinlimbsalvagetreatmentofosteosarcoma
AT lidongqi advancesinlimbsalvagetreatmentofosteosarcoma
AT yangyihao advancesinlimbsalvagetreatmentofosteosarcoma
AT yangzuozhang advancesinlimbsalvagetreatmentofosteosarcoma